1.47
1.47 (0%)
As of Apr 28, 2025
PLIANT THERAPEUTICS, INC. [PLRX]
Source:
Company Overview
Pliant Therapeutics, Inc. is a late-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Our initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-β
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | 650-481-6770 |
| Industry | manufacturing |
| CEO | Bernard Coulie, M.D., Ph.D. |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-228.4 |
| Net Income | $-210.3 |
| Net Cash | $8 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -46.3% |
| Profit as % of Stockholder Equity | -69.2% |
Management Effectiveness
| Return on Equity | -69.2% |
| Return on Assets | -53% |
| Turnover Ratio | |
| EBITA | $-228.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $396.9 |
| Total Liabilities | $92.9 |
| Operating Cash Flow | $-155.5 |
| Investing Cash Flow | $140.3 |
| Financing Cash Flow | $23.1 |
